Prelude Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Prelude Therapeutics şirketinin toplam hissedar öz sermayesi $156.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $197.2M ve $40.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$153.63m
Eşitlik	US$156.43m
Toplam yükümlülükler	US$40.79m
Toplam varlıklar	US$197.22m

Son finansal sağlık güncellemeleri

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Oct 27

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PRLD 'nin kısa vadeli varlıkları ( $156.4M ) kısa vadeli yükümlülüklerini ( $22.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: PRLD şirketinin kısa vadeli varlıkları ( $156.4M ) uzun vadeli yükümlülüklerini ( $18.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PRLD borçsuzdur.

Borcun Azaltılması: PRLD şirketinin 5 yıl önce borç/öz sermaye oranı 1.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PRLD şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: PRLD serbest nakit akışı her yıl % 25.4 1.2 yıl yetecek nakit akışına sahip olacaktır.

Prelude Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Recent updates

Price target increased by 12% to US$6.50

Price target decreased by 10.0% to US$5.40

Prelude Therapeutics Incorporated Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

New minor risk - Market cap size

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 14, 2024

Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Insufficient new directors

Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding

Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding

New major risk - Revenue and earnings growth

Price target decreased by 9.7% to US$7.00

New minor risk - Market cap size

Price target decreased by 22% to US$7.75

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

New minor risk - Share price stability

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Founder recently bought US$67k worth of stock

President & Chief Medical Officer exercised options and sold US$81k worth of stock

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Founder recently bought US$98k worth of stock

Price target decreased to US$9.60

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Prelude downgraded at Morgan Stanley ahead of key update

Price target decreased to US$11.60

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 2000 Growth Index

Price target increased to US$30.00

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 17, 2022

Price target decreased to US$25.25

Deborah Morosini Resigns as an Officer of Prelude Therapeutics Incorporated and Will Transition into a Role of Strategic Advisor to the President

Executive VP & Head of Chemistry exercised options to buy US$237k worth of stock.

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Price target increased to US$44.00

Price target decreased to US$38.00

Executive VP & Head of Chemistry recently bought US$95k worth of stock

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Chief Financial Officer Brian Piper has left the company

Insider exercised options and sold US$87k worth of stock

Price target decreased to US$47.20

Chief Medical Officer exercised options and sold US$436k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$77k worth of stock

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$681k worth of stock

Chief Medical Officer exercised options and sold US$384k worth of stock

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 3000E Value Index

Chief Medical Officer exercised options and sold US$458k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$574k worth of stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Chief Medical Officer exercised options and sold US$725k worth of stock

Chief Medical Officer notifies of intention to sell stock

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

New 90-day high: US$90.03

Prelude Therapeutics Incorporated Announces Board Changes

Independent Director has left the company

Prelude Therapeutics Incorporated has completed a Follow-on Equity Offering in the amount of $150 million.

Prelude Therapeutics prices $150M share offering

Prelude Therapeutics readies public offering

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares